Preferred Label : Opdivo;
Origin ID : M000602504;
Related record
- Semantic type(s)
https://www.has-sante.fr/jcms/p_3527277/fr/opdivo-nivolumab-cancer-bronchique-cbnpc
2024
false
false
false
France
evaluation of the transparency committee
Nivolumab
cancer
Malignant Neoplasm
bronchus, nos
neoplasm, malignant
Bronchial
carcinoma, non-small-cell lung
Opdivo
nivolumab
Nivolumab
---
https://www.has-sante.fr/jcms/p_3574980/fr/opdivo-nivolumab-et-yervoy-ipilimumab-cancer-colorectal
2024
false
false
false
France
Ipilimumab/Nivolumab Regimen
evaluation of the transparency committee
Ipilimumab
Nivolumab
Opdivo
ipilimumab
colorectal neoplasms
yervoy
nivolumab
---
https://www.has-sante.fr/jcms/p_3478087/fr/opdivo-yervoy-ipilimumab/nivolumab-cancer-de-l-oesophage
2023
France
evaluation of the transparency committee
Nivolumab
esophageal neoplasms
Ipilimumab
yervoy
esophagospasm
cancer of esophagus
Childhood Esophageal Carcinoma
neoplasm, malignant
Opdivo
---
https://www.has-sante.fr/jcms/p_3334854/fr/opdivo-nivolumab-adenocarcinome-gastrique-de-la-jonction-oeso-gastrique-ou-de-l-oesophage
2022
false
false
false
France
French
evaluation of the transparency committee
adenocarcinoma of esophagus
traction
Nivolumab
Opdivo
adenocarcinoma
esophagospasm
Esophagus
esophagogastric junction
nivolumab
indication of
stomach, nos
adenocarcinoma of esophagus
indicators and reagents
Esophagus
indicators
Esophagus adenocarcinoma
junctional
---
https://www.has-sante.fr/jcms/p_3332767/fr/opdivo-nivolumab-carcinome-epidermoide-de-l-oesophage
2022
false
false
false
France
French
evaluation of the transparency committee
Esophagus squamous cell carcinoma
Nivolumab
esophagus
esophagospasm
registries
carcinoma, squamous cell
Esophagus
Opdivo
Esophagus
nivolumab
Esophageal Squamous Cell Carcinoma
---
https://www.has-sante.fr/jcms/p_3381119/fr/opdivo-/-yervoy-nivolumab/ipilimumab-cbnpc
2022
France
evaluation of the transparency committee
yervoy
Opdivo
carcinoma, non-small-cell lung
---
https://www.has-sante.fr/jcms/p_3297501/fr/opdivo-10-mg/ml-nivolumab-carcinome-a-cellules-renales-avance-en-association-cabozantinib
2021
France
evaluation of the transparency committee
carcinoma
Cell
Carcinoma
kidney, nos
Opdivo
"u" lymphocyte
cells
nivolumab
association
carcinoma, renal cell
Nivolumab
cabozantinib
---
https://www.has-sante.fr/jcms/p_3290311/fr/opdivo-nivolumab-et-yervoy-ipilimumab-cancer-colorectal-metastatique
2020
false
false
false
France
Ipilimumab/Nivolumab Regimen
evaluation of the transparency committee
ipilimumab
yervoy
Opdivo
Colorectal cancer
nivolumab
colorectal neoplasms
neoplasm, malignant
Ipilimumab
Nivolumab
cancer
malignant neoplasm colon/rectum
---
https://www.has-sante.fr/jcms/p_3297497/fr/opdivo-10-mg/ml-/-yervoy-5-mg/ml-nivolumab-en-association-a-l-ipilimumab-cancer-colorectal-metastatique
2020
false
false
false
France
Ipilimumab/Nivolumab Regimen
evaluation of the transparency committee
indicators and reagents
indicators
cancer
neoplasm, malignant
ipilimumab
yervoy
Colorectal cancer
nivolumab
traction
indication of
association
colorectal neoplasms
Ipilimumab
Opdivo
Nivolumab
malignant neoplasm colon/rectum
---
https://www.has-sante.fr/jcms/p_3287835/fr/opdivo-nivolumab-et-yervoy-ipilimumab
2020
false
false
false
France
Ipilimumab/Nivolumab Regimen
evaluation of the transparency committee
yervoy
Opdivo
Ipilimumab
ipilimumab
Nivolumab
nivolumab
---
https://www.has-sante.fr/portail/jcms/c_2870207/fr/opdivo
2018
false
false
false
false
France
French
evaluation of the transparency committee
Opdivo
antibodies, monoclonal
Nivolumab
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/opdivo-lymphome-hodgkin-4518.html
2018
false
false
false
Canada
French
drug information
Opdivo
---
https://www.has-sante.fr/portail/jcms/c_2894915/en/opdivo
2018
false
false
false
France
evaluation of the transparency committee
Opdivo
antibodies, monoclonal
Nivolumab
---
